We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+25.98%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$293M
Cap. Flow
+$59.1M
Cap. Flow %
3.53%
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5

Top Buys

1
IRON icon
Disc Medicine
IRON
+$23.2M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$20.3M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.6M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$13.3M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Top Sells

1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$11.6M
2
PCVX icon
Vaxcyte
PCVX
+$11M
3
RNAM
Avidity Biosciences
RNAM
+$7.67M
4
COGT icon
Cogent Biosciences
COGT
+$7.55M
5
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$6.46M

Sector Composition

1 Healthcare 99.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$3.62B
$17M 1.01%
830,983
– –
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.09B
$16.6M 0.99%
+2,142,855
New +$12.2M
TRVI icon
28
Trevi Therapeutics
TRVI
$2.44B
$16.4M 0.98%
6,881,090
+217,500
+3% +$548K
MORF
29
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$15.2M 0.91%
265,511
+51,271
+24% +$2.68M
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$12.5M 0.75%
393,000
– –
RETA
31
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.2M 0.61%
+100,430
New +$9.5M
MGNX icon
32
MacroGenics
MGNX
$257M
$9.65M 0.58%
1,803,204
+100,000
+6% +$617K
REPL icon
33
Replimune Group
REPL
$781M
$8.98M 0.54%
386,762
-300,000
-44% -$5.86M
AUTL
34
Autolus Therapeutics
AUTL
$394M
$8.92M 0.53%
3,746,857
– –
PRTA icon
35
Prothena Corp
PRTA
$432M
$8.73M 0.52%
127,900
– –
NTLA icon
36
Intellia Therapeutics
NTLA
$1.64B
$8.31M 0.5%
203,684
– –
ARVN icon
37
Arvinas
ARVN
$517M
$7.08M 0.42%
285,331
– –
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.12B
$5.8M 0.35%
749,022
+66,561
+10% +$561K
IMVT icon
39
Immunovant
IMVT
$7.95B
$5.69M 0.34%
300,000
-285,759
-49% -$5.33M
BLUE
40
DELISTED
bluebird bio
BLUE
$5.63M 0.34%
85,495
+13,457
+19% +$984K
DCPH
41
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.21M 0.31%
+370,000
New +$5.29M
SLN
42
Silence Therapeutics
SLN
$494M
$4.85M 0.29%
881,173
– –
GRTS
43
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$4.68M 0.28%
2,401,714
-2,760,634
-53% -$6.46M
STRO icon
44
Sutro Biopharma
STRO
$394M
$3.63M 0.22%
78,000
-99,648
-56% -$4.96M
ADCT icon
45
ADC Therapeutics
ADCT
$163M
$3.54M 0.21%
1,647,030
– –
ACRS icon
46
Aclaris Therapeutics
ACRS
$740M
$2.74M 0.16%
264,377
– –
PASG icon
47
Passage Bio
PASG
$16.1M
$1.74M 0.1%
92,500
-95,346
-51% -$1.89M
NAMSW icon
48
NewAmsterdam Pharma Warrant
NAMSW
$94.6M
$1.05M 0.06%
500,333
– –
ALLK
49
DELISTED
Allakos
ALLK
– –
-1,112,684
Closed -$4.95M
RNAM
50
DELISTED
Avidity Biosciences
RNAM
– –
-500,000
Closed -$7.67M
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return